Jazz Pharmaceuticals (JAZZ) Non-Current Debt (2010 - 2026)

Jazz Pharmaceuticals' Non-Current Debt history runs 16 years deep, the most recent figure standing at $4.3 billion for Q1 2026.

• On a quarterly basis, Non-Current Debt fell 19.44% year-over-year to $4.3 billion in Q1 2026; TTM through Mar 2026 was $4.3 billion, a 19.44% decrease from a year earlier, with the FY2025 full-year figure at $5.4 billion, down 11.84% from the prior year.
• Non-Current Debt declined to $4.3 billion in Q1 2026 per JAZZ's latest filing, from $5.4 billion in the prior quarter.
• Across five years, Non-Current Debt topped out at $6.1 billion in Q3 2024 and bottomed at $4.3 billion in Q1 2026.
• The 5-year median for Non-Current Debt is $5.7 billion (2023), against an average of $5.5 billion.
• Across the five-year window, Non-Current Debt jumped 223.41% in 2022 and slipped 19.44% in 2026, its largest moves.
• Year by year, Non-Current Debt stood at $5.7 billion in 2022, then slipped by 10.28% to $5.1 billion in 2023, then advanced by 18.98% to $6.1 billion in 2024, then declined by 11.84% to $5.4 billion in 2025, then retreated by 19.3% to $4.3 billion in 2026.
• Per Business Quant, the three latest JAZZ Non-Current Debt figures stand at $4.3 billion (Q1 2026), $5.4 billion (Q4 2025), and $5.4 billion (Q3 2025).